BERLIN (Reuters) – The granting of intellectual property waivers is not the right way to maximise output of COVID-19 vaccines, the founder of German vaccine maker BioNTech said on Wednesday, as he instead advocated the award of production licences.
“This is not a solution,” CEO Ugur Sahin said in response to reports that U.S. President Joe Biden’s administration was considering such waivers as one option for maximising production and supply of vaccines.
(Reporting by Douglas Busvine; Editing by Madeline Chambers)
